Ikena Oncology, Inc.

IKNA

US45175G1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 08/06/2024 am IST			5-day change	1st Jan Change
1.75 ^USD	-0.57%		-1.13%	-11.17%

29/05	HC Wainwright Adjusts Price Target on Ikena Oncology to $4 From $11, Maintains Buy Rating	MT
29/05	Wedbush Downgrades Ikena Oncology to Neutral From Outperform After Discontinuation of Lead Program IK-930, Adjusts PT to $2 From $8	MT

Ikena Oncology, Inc. Appoints Otello Stampacchia as Board of Directors

January 05, 2021 at 05:30 pm IST

Ikena Oncology, Inc. announced that Otello Stampacchia, Ph.D., Managing Director of Omega Funds, will join Ikena’s Board of Directors.

Latest news about Ikena Oncology, Inc.

HC Wainwright Adjusts Price Target on Ikena Oncology to $4 From $11, Maintains Buy Rating	29/05	MT
Wedbush Downgrades Ikena Oncology to Neutral From Outperform After Discontinuation of Lead Program IK-930, Adjusts PT to $2 From $8	29/05	MT
Ikena Oncology to Cut Jobs, Explore Options, End IK-930 Program; Shares Rise After Hours	29/05	MT
Ikena Oncology, Inc. Announces Workforce Reduction	29/05	CI
Ikena Oncology, Inc. Announces Discontinue Development of IK-930	29/05	CI
Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03	CI
North American Morning Briefing : Inflation Data -2-	12/03	DJ
Ikena Oncology, Inc. Announces Executive Changes	22/02	CI
Ikena Oncology to Cut 35% of Workforce to Extend Cash Runway Into H2 2026	19/01	MT
Ikena Oncology, Inc. Provides Corporate Updates	19/01	CI
Top Premarket Decliners	24/11	MT
HC Wainwright Adjusts Ikena Oncology Price Target to $11 From $18, Maintains Buy Rating	10/11	MT
Wedbush Lowers Ikena Oncology's Price Target to $8 From $11, Moves Estimates Launch Timings for IK-930; Maintains Outperform Rating	10/11	MT
Ikena Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Ikena Oncology, Inc. Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial	09/11	CI
North American Morning Briefing : Stocks Look to -2-	06/11	DJ
Wedbush Starts Ikena Oncology at Outperform With $11 Price Target	22/23/22	MT
Certain Common Stock of Ikena Oncology, Inc. are subject to a Lock-Up Agreement Ending on 14-AUG-2023.	14/23/14	CI
Ikena Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Ikena Oncology Shares Fall After Pionyr Immunotherapeutics Acquisition Completed	08/23/08	MT
Ikena Oncology Completes Acquisition of Pionyr Immunotherapeutics in All-Stock Deal	07/23/07	MT
Ikena Oncology, Inc. acquired Pionyr Immunotherapeutics Inc..	04/23/04	CI
Ikena Oncology, Inc.(NasdaqGM:IKNA) added to Russell Small Cap Comp Value Index	23/23/23	CI
Ikena Oncology, Inc.(NasdaqGM:IKNA) added to Russell 3000 Index	23/23/23	CI

Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.75 USD

Average target price

3 USD

Spread / Average Target

+71.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IKENA ONCOLOGY, INC.	-11.17%	84.45M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research